Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study.
U
U
Platzbecker
F
F
Braulke
A
A
Kündgen
K
K
Götze
G
G
Bug
C
C
Schönefeldt
K
K
Shirneshan
C
C
Röllig
M
M
Bornhäuser
R
R
Naumann
J
J
Neesen
A
A
Giagounidis
W-K
WK
Hofmann
G
G
Ehninger
U
U
Germing
D
D
Haase
M
M
Wermke
D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000627:therapeutic use*; D001374:Azacitidine / Q000008:administration & dosage / Q000627:therapeutic use*; D002872:Chromosome Deletion; D002895:Chromosomes, Human, Pair 5; D006801:Humans; D000077269:Lenalidomide; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000235:genetics; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000235:genetics; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000964:Antimetabolites, Antineoplastic; D013792:Thalidomide; D000077269:Lenalidomide; D001374:Azacitidine